Circulating cell-free DNA has a high degree of specificity to detect exon 19 deletions and the single-point substitution mutation L858R in non-small cell lung cancer

Ähnliche Einträge

• 3D radiomics predicts EGFR mutation, exon-19 deletion and exon-21 L858R mutation in lung adenocarcinoma
  von: Liu, Guixue, et al.
  Veröffentlicht: (2020)
• Are exon 19 deletions and L858R EGFR mutations in non-small-cell lung cancer clinically different?
  von: Costa, D B, et al.
  Veröffentlicht: (2007)
• Brain metastases in patients with non-small cell lung cancer: the role of mutated-EGFRs with an exon 19 deletion or L858R point mutation in cancer cell dissemination
  von: Hsiao, Shih-Hsin, et al.
  Veröffentlicht: (2017)
• The Difference of Clinical Characteristics Between Patients With Exon 19 Deletion and Those With L858R Mutation in Nonsmall Cell Lung Cancer
  von: Zhang, Yaxiong, et al.
  Veröffentlicht: (2015)
• U.S. Food and Drug Administration Approval Summary: Erlotinib for the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 19 Deletions or Exon 21 (L858R) Substitution Mutations
  von: Khozin, Sean, et al.
  Veröffentlicht: (2014)